104 results about "Arterial thrombus" patented technology

An apparatus and method for stabilization of aneurysm is disclosed. The apparatus comprises an ultraviolet radiation generator for generating UV radiation having a wavelength, strongly absorbed by the DNA and a catheter including means for delivering the ultraviolet radiation to the aneurysm. The distal end of the catheter is placed inside the aneurysm. Stabilization of the aneurysm is achieved by forming a mural arterial thrombus inside the aneurysm. To make irradiation possible, the blood is displaced from the aneurysm by a steady stream of UV radiation transparent fluid. The injury to the endothelium that triggers the thrombus formation is caused by UV radiation delivered to the aneurysm. In several days after intervention the thrombus becomes fully organized, leaving on the inside surface of the aneurysm a thick layer of fibrotic tissue that stabilizes the aneurysm.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Tyr-Ile-Gly-Ser-Arg, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb / IIIa expression, and discloses the activity of inhibiting the P-selectin expression in vivo. Therefore,the invention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb / IIIa antagonist and the application in preparing P-selectin antagonist. The formulas are shown in the decription.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Ser, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb / IIIa expression, and discloses the activity of inhibiting the P- selectin expression in vivo. Therefore, theinvention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb / IIIa antagonist and the application in preparing P- selectin antagonist. The formulas are shown in the decription.

The invention, belonging to the technical field of medicine, relates to a bi-functional anti-platelet aggregation medicine and an application of the medicine in preventing and treating arterial tlirombotic diseases. The medicine of the invention has both a P2Y12 receptor antagonist property and a phosphodiesterase inhibitory activity. The results of in vivo and in vitro anti-platelet aggregation activity experiments of the medicine provide the anti-platelet mechanism of the medicine, the structural formula and anti-platelet mechanism of the medicine are different from those of known anti-platelet medicines, aspirin, Clopidogrel, Prasugrel, Cilostazol, and platelet and fibrinogen receptor antagonist. The medicine of the invention has good inhibition effect to various platelet aggregation induced by agonists. The results of mice in vivo experiment models of arterial thrombosis show that the medicine of the invention has significantly similar antithrombotic activity with Clopidogrel and non-obvious side effect of hemorrhage. The medicine of the invention can be used as antithrombotic medications for treating coronary heart disease, apoplexy and other arterial tlirombotic diseases.

The present invention discloses three materials such as warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe, preparation methods, anti-arterial thrombus activities, anti-venous thrombosis activities, in vivo vitamin K content lowering activities, in vivo blood coagulation factor II content lowering activities, platelet aggregation inhibition activities thereof, and in vivo platelet membrane glycoprotein IIb / IIIa (GPIIb / IIIa) content lowering activities thereof, and discloses the advantages of no warfarin-like bleeding risk in warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe, such that the invention discloses applications of warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe in preparation of anti-arterial thrombus drugs, anti-venous thrombosis drugs, platelet aggregation inhibition drugs, GPIIb / IIIa antagonists, vitamin K antagonists, and blood coagulation factor II antagonists.

The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

The invention discloses (3S)-1,1-dimethylol-tetrahydro-beta-carboline-3-formyl-Gly-Leu-Asp-Val, a preparation method, anti-arterial-thrombus activity, anti-venous-thrombosis activity, GPIIb / IIIa expression inhibiting activity and P-selectin expression inhibition activity thereof, such that the prevent invention discloses applications of the (3S)-1,1-dimethylol-tetrahydro-beta-carboline-3-formyl-Gly-Leu-Asp-Val in preparation of anti-arterial-thrombus drugs, anti-venous-thrombosis drugs, GPIIb / IIIa antagonists and P-selectin antagonists. The structure formula is defined in the specification.

The invention discloses warfarin-4-O-acetyl-Leu-Asp-Val, a preparation method, anti-arterial thrombus activity, anti-venous thrombosis activity, in vivo platelet membrane glycoprotein IIb / IIIa (GPIIb / IIIa) content lowering activity, in vivo vitamin K content lowering activity, in vivo blood coagulation factor II content lowering activity, and platelet aggregation inhibition activity thereof, such that the invention discloses applications of warfarin-4-O-acetyl-Leu-Asp-Val in preparation of anti-arterial thrombus drugs, anti-venous thrombosis drugs, platelet aggregation inhibition drugs, GPIIb / IIIa antagonists, vitamin K antagonists, and blood coagulation factor II antagonists.

Disclosed is a micro-emulsifier comprising a stack of piezoelectric materials, a horn at a proximal end of the stack of piezoelectric materials, and a transmission wire receivable in the horn for transmission of ultrasound waves able to be produced by the stack of piezoelectric materials. The ultrasound waves are able to be produced in a direction parallel to a longitudinal axis of the stack of piezoelectric materials and the horn. The transmission wire comprises a first end receivable in the horn and a second end remote from the first end, the second end having a bulb thereon.

The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Phe, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb / IIIa expression, and discloses the activity of inhibiting the P-selectin expression in vivo. Therefore, theinvention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb / IIIa antagonist and the application in preparing P- selectin antagonist. The formulas are shown in the decription.

The invention discloses a thrombolytic efficacy evaluation method based on a two-photon microscope technology. The thrombolytic efficacy evaluation method comprises the following steps: (1) establishing a cerebral thrombosis animal model of a living animal in a waking state, wherein the cerebral thrombosis animal model comprises an arterial thrombosis model and a venous thrombosis model; (2) carrying out fluorescence labeling on a thrombolytic drug by adopting fluorescein isothiocyanate to obtain a fluorescein isothiocyanate labeled thrombolytic drug; (3) injecting the fluorescein isothiocyanate labeled thrombolytic drug into the caudal vein of the cerebral thrombosis animal model; (4) detecting hemodynamics and vascular morphological changes after thrombolytic drug treatment, and observing changes of blood oxygen pressure after thrombolytic drug treatment; (5) observing the change of the cerebral infarction area after thrombolytic drug treatment, and judging the cerebral area range affected by thrombus; and (6) judging the efficacy of the thrombolytic drug according to the result. The method has the characteristic that the efficacy of the thrombolytic drug can be directly evaluated.

The invention discloses S,R-heptacyclic aldehyde-Tyr-Ile-Gly-Ser-AA (wherein AA is a Lys residue or an Arg residue), a preparation method thereof, anti-venous thrombosis activity thereof, anti-arterythrombosis activity thereof, activity thereof for inhibiting the expression of GPIIb / IIIa in vivo, and activity thereof for inhibiting the expression of P-selectin in vivo. Therefore, the invention discloses application of the S,R-heptacyclic aldehyde-Tyr-Ile-Gly-Ser-AA in preparation of anti-venous thrombosis drugs, application of the S,R-heptacyclic aldehyde-Tyr-Ile-Gly-Ser-AA in preparation ofanti-arterial thrombosis drugs, application of the S,R-heptacyclic aldehyde-Tyr-Ile-Gly-Ser-AA in preparation of GPIIb / IIIa antagonists and application of the S,R-heptacyclic aldehyde-Tyr-Ile-Gly-Ser-AA in preparation of P-selectin antagonists.

The invention discloses fresh grapefruit pulp aqueous extract powder, a preparation method thereof and an application of the fresh grapefruit pulp aqueous extract powder to the aspect of resisting venous thrombosis and arterial thrombosis. The fresh grapefruit pulp aqueous extract powder prepared by the method provided by the invention contains 15 quinic acid compounds and 10 flavonoid compounds.Experiments prove that the fresh grapefruit pulp aqueous extract powder has good effect of resisting venous thrombosis and arterial thrombosis, so that the fresh grapefruit pulp aqueous extract powderprovides an effective technical means for treating venous thrombosis and arterial thrombosis.

The invention provides an oligopeptide R-G-S(p)-L-P capable of influencing platelet function or trim / derivate thereof and application of the oligopeptide R-G-S(p)-L-P or trim / derivate thereof in preventing and / or treating arterial thrombus disease and / or related disease interacted by platelet GPIbalpha and ABP. The platelet treated by the oligopeptide R-G-S(p)-L-P or trim / derivate thereof can effectively inhibit adhesion function of the platelet including ristomycin induced platelet aggregation function without influencing platelet aggregation function including ADP induced platelet aggregation function, thus inhibiting thrombopoiesis while basically maintaining the integrity of platelet functional status. The invention can be directly used for research and development of clinical anti-thrombus medicine.

The invention discloses a traditional Chinese medicine preparation for preventing and treating thrombus. The traditional Chinese medicine preparation is characterized by comprising leech, earthworm, safflowers, salvia miltiorrhiza, panax notoginseng, radix isatidis, honeysuckle and dandelion; the leech, the earthworm, the safflowers, the salvia miltiorrhiza, the panax notoginseng, the radix isatidis, the honeysuckle and the dandelion are ground to obtain fine powder, and then the fine powder and honey are mixed with each other to obtain honeyed pills. The traditional Chinese medicine preparation has the advantages that traditional Chinese medicine varieties for preventing and treating the thrombus can be increased, the traditional Chinese medicine preparation is low in production cost, high in cure rate, suitable for preventing and treating venous thrombus, arterial thrombus and microcirculation thrombus diseases and also suitable for treating thrombus obstructive diseases with inflammation, and can become effective fast, and good thrombus preventing and treating effects can be realized.

The present invention discloses warfarin-4-O-acetyl-Tyr-Ile-Gly-Ser-Lys, a preparation method, anti-arterial thrombus activity, anti-venous thrombosis activity, in vivo vitamin K content lowering activity, in vivo blood coagulation factor II content lowering activity, and platelet aggregation inhibition activity thereof, such that the invention discloses applications of warfarin-4-O-acetyl-Tyr-Ile-Gly-Ser-Lys in preparation of anti-arterial thrombus drugs, anti-venous thrombosis drugs, platelet aggregation inhibition drugs, vitamin K antagonists, and blood coagulation factor II antagonists.

The invention discloses 3S-1-(1,1-dimethyl-1,3-dioxane-6-spiroyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Glu as shown in the following formula, as well as a preparation method and an anti-arterial thrombosis activity thereof. Therefore, the invention discloses application of the compound in preparation of anti-arterial thrombosis drugs.

The invention provides a molecular PAD4 inhibitor as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Two functional groups are adopted to modify an amino acid skeleton, one functional group is NBD-Cl with the characteristics of low polarity and strong fluorescence, the NBD-Cl is used for modifying the N end of the amino acid skeleton and can be used for subcellular imaging; in addition, due to the fact that the NBD-Cl is small in relative size and lacks reaction orthogonality, interference on the biochemical reaction of organisms is small; the other one is PBA with tumor targeting, the PBA can be combined with a cell membrane by recognizing a cis-diol unit of glycoprotein, the PBA / cis-diol interacts, and a formed dynamic covalent bond can be regulated and controlled by regulating the pH value or adding competitive molecules, so a controllable self-assembly system is realized. The small-molecule PAD4 inhibitor has good oral activity, has an inhibiting effect on tumor growth and metastasis of mice, and also has a treatment effect on arterial thrombosis of rats.

The invention discloses (3S)-1,1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-Gly-Gly-Pro-Arg-Pro, a preparation method, anti-arterial-thrombus activity, anti-venous-thrombosis activity, GPIIb / IIIa expression inhibition activity and P-selectin expression inhibition activity thereof, such that the present invention discloses applications of the(3S)-1,1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-Gly-Gly-Pro-Arg-Pro in preparation of anti-arterial-thrombus drug, anti-venous-thrombosis drugs, GPIIb / IIIa antagonists and P-selectin antagonists. The formula is defined in the specification.

The invention discloses (3S)-1,1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-The, a preparation method of the compound, and anti-arterial thrombosis activity of the compound. The invention further discloses an application of the compound in the preparation of antithrombotic drugs.

The invention discloses two flavane derivatives extracted and separated from dragon's blood and an application of pharmaceutical compositions thereof in preparation of drugs for preventing or treating thromboembolic diseases, and especially the flavane derivatives used for preparing medicines for preventing or treating cerebral arterial thrombosis, myocardial infarction, unstable angina pectoris, peripheral arterial thrombosis, restenosis after angioplasty or endarterectomy, deep venous thrombosis and pulmonary thrombosis.

The invention discloses a Sj13 polypeptide, sourced from schistosoma japonicum, and a mutant thereof. Through gene engineering technology, a recombinant polypeptide Sj13 and a mutant thereof are obtained; through APTT, PT and TT coagulation function detection, it is identified that the Sj13 and the mutant thereof have excellent in-vitro anti-coagulation function; enzyme kinetics test detection proves that the Sj13 polypeptide and the mutant thereof have functions of inhibiting coagulation related factors XIa, Xa and Plasmin; a mouse FeCl3 damaging common carotid artery thrombus model proves that the Sj13 can inhibit generation of common carotid artery thrombus, has antithrombus effect and is low in bleeding risk. The Sj13 and the mutant thereof have important value of development and application of anti-coagulation and antithrombus medicines.

The invention discloses fresh elm leaf aqueous extract powder, a preparation method of the fresh elm leaf aqueous extract powder and an effect of the fresh elm leaf aqueous extract powder in resistingvenous thrombosis and arterial thrombosis. The fresh elm leaf aqueous extract powder prepared by the method provided by the invention contains 17 quinic acid compounds and 14 quercetin compounds. Experiments prove that the fresh elm leaf aqueous extract powder disclosed by the invention can effectively inhibit the venous thrombosis and the arterial thrombosis, so that the invention discloses application of the fresh elm leaf aqueous extract powder in preparation of anti-venous thrombosis and anti-arterial thrombosis medicines. The invention provides an effective technical means for thrombus treatment.

The invention provides a molecular PAD4 inhibitor and its preparation method and application, belonging to the technical field of biomedicine. The present invention uses two functional groups to modify the amino acid skeleton, one is NBD-Cl with low polarity and strong fluorescence characteristics, and it can be used for subcellular imaging by modifying the N-terminal of the amino acid skeleton. Small, lacks reaction orthogonality, and has little interference with the biochemical reactions of the organism itself; the other is a tumor-targeted PBA that can bind to the cell membrane by recognizing the cis-diol unit of the glycoprotein. This PBA / cis Diol interactions can also regulate the formation of dynamic covalent bonds by adjusting the pH value or adding competing molecules to achieve a controllable self-assembly system. The small molecule PAD4 inhibitor of the present invention has good oral activity, has inhibitory effect on mouse tumor growth and metastasis, and has therapeutic effect on rat arterial thrombus.

Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor / factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and / or arterial thrombi in vivo.

The invention relates to a pulmonary artery thrombus treatment platform which comprises a suction catheter, a thrombus breaking device and a suction pump, wherein the thrombus breaking device comprises one or more of a first thrombus breaking assembly, a second thrombus breaking assembly and a third thrombus breaking assembly; the first thrombus breaking assembly comprises a first catheter I, a first catheter II and a first stirrer; the first stirrer comprises a plurality of mesh baskets which are sequentially arranged along the axis of the first catheter, and the maximum diameters of the meshbaskets are sequentially reduced from the far end to the near end when the mesh baskets are in an open state; the second thrombus breaking assembly comprises a second catheter II, a second catheter II and a second stirrer; the second stirrer is linear and is bent in an open state; the third thrombus breaking assembly comprises a third catheter I, a third catheter II and a third stirrer; and the third stirrer is sheet-shaped and is bent in an open state. The pulmonary artery thrombus treatment platform can remove pulmonary artery thrombus under the condition that relative safety is guaranteed,and is particularly suitable for removing thrombus at pulmonary artery and capillary bifurcation positions.

The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to prevention of acute arterial thrombotic syndromes.